U.S. Markets closed

What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price

NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery. The company's stock dropped 67 percent that day.

Potential catalyst, pipeline and analysts target price available here, no obligation READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/histogenics/

The company still plans to seek FDA approval based on the data released in September. The company could be helped by the fact that the FDA has changed the guidelines for cartilage repair studies since Histogenics started its trials.

Histogenics announced that the U.S. Food and Drug Administration (the FDA) has granted a Type C meeting to discuss the top-line results from the NeoCart Phase 3 clinical trial and Histogenics' planned Biologics License Application submission.

Find out when the FDA meeting is anticipated in this full report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/histogenics/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source